Susan G. Komen® Joins Forces With Heron Therapeutics To Raise Awareness Of The Supportive Care Needs Of Patients With Breast Cancer

Susan G. Komen and Heron Therapeutics, Inc. today announced that the two organizations have joined forces to encourage supporters to take action in the fight against breast cancer. Through their new partnership, Susan G. Komen and Heron Therapeutics strive to raise awareness of the importance of supportive care in breast cancer treatment, with the goal of allowing patients to complete their treatment regimens and thereby increase survival rates.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161129005564/en/

Through coordinated fundraising efforts, Susan G. Komen and Heron Therapeutics have launched a donation matching program (the Heron Matching Program) aimed at doubling funds raised in Susan G. Komen's 2016 year-end fundraising campaign. Heron Therapeutics and an affiliated partner have made a $250,000 donation to Susan G. Komen and have pledged to match dollar-for-dollar - up to a total commitment of $1 million - all Heron Matching Program donations made through December 31, 2016. The funds will be used by Komen to support its mission to save lives by meeting the most critical needs in local communities and investing in breakthrough research to prevent and cure breast cancer.

"Heron Therapeutics and Susan G. Komen share a common interest in improving the quality of life for breast cancer patients," said Susan G. Komen Senior Vice President of Development Christina Alford. "Addressing issues like nausea, vomiting and pain can help patients remain in treatment through the continuum of care and increase their opportunity for long-term survival. Support from Heron Therapeutics and the launch of the Heron Matching Program will support research and community programs, moving us closer to achieving our Bold Goal of reducing the current number of breast cancer deaths in the U.S. by 50 percent within the next decade."

Breast cancer is the second leading cause of cancer death among women in the U.S., and, this year alone, approximately 247,000 new cases of invasive breast cancer will be diagnosed in the U.S. 1 Among women diagnosed with breast cancer, 72% to 94% (depending on stage of disease) are treated with surgery, and chemotherapy is often part of the treatment plan. 2

"Despite available treatments, patients are still suffering from the debilitating effects of breast cancer surgery and chemotherapy, which result in difficult and painful recoveries that create understandable challenges to the continuation of treatment," said Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics. "Heron Therapeutics is dedicated to improving the lives of patients by developing best-in-class medicines that are aimed to offset these overwhelming side effects, and we invite the public to take action by donating to Komen in support of those currently battling breast cancer."

If you liked this article you might like

Here's Why Investors Should Steer Clear of Opioids

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

Biotech Stock Mailbag: Heron, Exelixis

Heron and the Never-Ending FDA Drug Review

Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!